Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer

Researchers determined that aggressive care at the end of life (EOL) leads to diminished quality of life, poor quality of care, and increased costs for patients with advanced lung cancer.

Influence of Surgical Options for Early-Stage Lung Cancer on Opioid Use

A research letter presents results of a study on opioid use among patients in the SEER database who underwent open resection vs VATS for non-small cell lung cancer.

SCOOPs Program Improves Patient Experience, Reduces Costs

Researchers report on the effectiveness results of the Supportive Care of Oncology Patients (SCOOPs) Program were presented at the 2018 ASCO Quality Care Symposium.

Lobectomy vs SBRT: A Comparison of Prognoses and Survival for Early-Stage NSCLC

A comparison study demonstrated the difference in survival rates between lobectomy and SBRT for early-stage non-small cell lung cancer.

Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Update on Patient Selection, Efficacy and Outcomes

[Lung Cancer: Targets and Therapy] This review presents a summary and update of the latest evidence for patient selection, efficacy and outcome of primary treatment, prophylactic cranial irradiation (PCI) in the treatment of patients with SCLC.

Preventative Medications Unnecessarily Prescribed to EOL Patients With Lung Cancer

In a retrospective study conducted in the United States and the United Kingdom, researchers evaluated the prescribing of preventative medications in patients with lung cancer discharged from hospital at the end of life.

Using Palliative Care to Improve Lung Cancer Outcomes in Veterans at Risk of Suicide

In a review of data from more than 20,000 veterans, researchers determined the effects of palliative care on suicide rates among veterans with advanced lung cancer.

Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)